Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05860881 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)

Study acronym: SiroSkin
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: May 15, 2026 to Sep 30, 2027 Start date: Jan 10, 2024 to Feb 9, 2024 · Trial status: Recruiting to Active, Not Recruiting · Completion date: Dec 30, 2026 to Sep 30, 2027 · 2 morev6 Show 5 more changesShow less
    • Start date: Jan 10, 2024 to Feb 9, 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Dec 30, 2026 to Sep 30, 2027
    • Site details revised at 6 of 6 sites
    • Publications: details revised at 1 of 1 entry
  2. Eligibility criteria expanded, about 15 words Publications: details revised at 1 of 1 entryv5 Show 1 more changeShow less
    • Publications: details revised at 1 of 1 entry

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 31, 2023 to Jan 10, 2024 · Eligibility criteria expanded, about 8 words · Secondary endpoints: 10 to 11 · 2 morev4 Show 5 more changesShow less
    • Start date changed from estimate of Oct 31, 2023 to Jan 10, 2024
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: 10 to 11
    • Study description revised
    • Site details revised at 6 of 6 sites

    See this version in full on ClinicalTrials.gov ↗

  4. Start date: Jul 15, 2023 to Oct 31, 2023v3
  5. Start date: May 15, 2023 to Jul 15, 2023v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
01.21 SiroSkin is a phase 3, double-blind, multi-centre, parallel-arm, randomised, placebo-controlled trial to evaluate the use of topical 1% sirolimus in the chemoprevention of skin cancer, versus placebo, applied every night for 24 weeks in solid organ transplant recipients.
Trial Details
NCT Number NCT05860881
Lead Sponsor Melanoma and Skin Cancer Trials Limited
Collaborators: Monash University, The University of Queensland
Conditions Solid Organ Transplant Recipients, Skin Cancer
Enrollment 146 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov